The serotonergic system in Parkinson's disease

Prog Neurobiol. 2011 Oct;95(2):163-212. doi: 10.1016/j.pneurobio.2011.08.004. Epub 2011 Aug 22.


Although the cardinal manifestations of Parkinson's disease (PD) are attributed to a decline in dopamine levels in the striatum, a breadth of non-motor features and treatment-related complications in which the serotonergic system plays a pivotal role are increasingly recognised. Serotonin (5-HT)-mediated neurotransmission is altered in PD and the roles of the different 5-HT receptor subtypes in disease manifestations have been investigated. The aims of this article are to summarise and discuss all published preclinical and clinical studies that have investigated the serotonergic system in PD and related animal models, in order to recapitulate the state of the current knowledge and to identify areas that need further research and understanding.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Disease Models, Animal
  • Humans
  • Molecular Targeted Therapy
  • Parkinson Disease / drug therapy
  • Parkinson Disease / physiopathology*
  • Protein Isoforms / agonists
  • Protein Isoforms / antagonists & inhibitors
  • Protein Isoforms / metabolism
  • Receptors, Serotonin / chemistry
  • Receptors, Serotonin / metabolism*
  • Serotonergic Neurons / drug effects
  • Serotonergic Neurons / metabolism*
  • Serotonin / chemistry
  • Serotonin / metabolism*
  • Synaptic Transmission* / drug effects


  • Protein Isoforms
  • Receptors, Serotonin
  • Serotonin